219 reports of this reaction
2.0% of all FLUVASTATIN SODIUM reports
#9 most reported adverse reaction
MYOCARDIAL INFARCTION is the #9 most commonly reported adverse reaction for FLUVASTATIN SODIUM, manufactured by Sandoz Inc. There are 219 FDA adverse event reports linking FLUVASTATIN SODIUM to MYOCARDIAL INFARCTION. This represents approximately 2.0% of all 11,133 adverse event reports for this drug.
Patients taking FLUVASTATIN SODIUM who experience myocardial infarction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYOCARDIAL INFARCTION is a less commonly reported adverse event for FLUVASTATIN SODIUM, but still significant enough to appear in the safety profile.
In addition to myocardial infarction, the following adverse reactions have been reported for FLUVASTATIN SODIUM:
The following drugs have also been linked to myocardial infarction in FDA adverse event reports:
MYOCARDIAL INFARCTION has been reported as an adverse event in 219 FDA reports for FLUVASTATIN SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYOCARDIAL INFARCTION accounts for approximately 2.0% of all adverse event reports for FLUVASTATIN SODIUM, making it a notable side effect.
If you experience myocardial infarction while taking FLUVASTATIN SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.